Metadata
Author: Literature
Data
English[en]
Those with mutations in KIT or PDGFRA often respond to the tyrosine kinase inhibitor imatinib.
Spanish[es]
Los tumores con mutaciones de KIT o PDGFRA responden con frecuencia al imatinib, inhibidor de la tirosina cinasa.